South Africa: Evergreening

Last Updated: 22 April 2013
Article by Rowen Forster and Kirsten-Lee Dinnes

Most Read Contributor in South Africa, September 2018

The decision of the Indian Supreme Court to deny Novartis’s application for patent protection for an improved version of its patented Glivec drug – the culmination of a seven-year battle - has certainly made the headlines. There are a number of reasons for this. First, Glivec is a well-known drug – described by some as a ‘wonder drug’ – that’s used to combat cancer, including  leukaemia and gastro-intestinal cancer. Second,  pharmaceutical patents are inherently controversial because they’re emotive – pharmaceutical companies argue that they deserve as much protection as they can get because so much research and development goes into drugs,  whereas civil society often argues that patents allow the drugs companies to charge a premium, thereby placing life-saving drugs beyond the reach of much of the world’s population . And third, the Glivec case dealt with the issue  of ‘evergreening’,  which is the practice of patenting modifications  or improvements to a patented drug, and thereby extending the 20-year protection granted by the original patent. 

It’s  no coincidence that this high-profile drama played itself out in India – with its population of 1.2 billion people, India is one of the most important and fastest growing pharmaceutical markets in the world. India is also the centre of the world’s generic drug industry.  And it’s  a country where few people can afford Glivec, but where  generic versions of that drug sell for some 1/10th of the price of the original product.

The  facts of the case were straightforward.  Novartis applied to patent the updated version of Glivec, claiming that the new compound was a significant improvement  in that  the original compound was never really suitable  for making a pill, and that the development of a chemically stable form took a great deal of extra work. The court, however, ruled that the new patent did not satisfy the requirement of novelty,  being no more than an  amended version of a known compound, namely that of the original Glivec – novelty does, of course, lie at the very heart of the patent system, which rewards  new inventions through monopoly protection.  The comments released after the announcement of the Novartis decision show just how wide the divide is – a Novartis spokesman said that the decision ‘discourages innovative drug discovery essential to advancing medical science for patients’, whereas a spokesman for one of the groups opposed to the patent said that the decision would ‘go a  long way in providing affordable medicine for the poor’.  The commercial importance of the case was illustrated by the fact that the  Novartis  share price dropped  on the announcement of the decision, whereas the share price of a major generics company rose sharply. The decision was also not good news for the pharmaceutical companies Pfizer and Roche, who are both facing similar legal issues in India

The Novartis decision certainly  raises questions about the patent system in general.  As a result of the extraordinary amount of patent litigation that’s been going on in the field of mobile devices -  for example Apple v Samsung - a certain amount of soul searching has been taking place. A highly-respected US patent judge and academic,  Richard Posner, has, for example, queried whether patent protection should be the same for all inventions , suggesting that  short-lifespan products like mobile devices should also have a short term of patent protection.   Even more controversially,  he  has suggested that  ‘most industries could get along fine without patent protection’ . But  it’s significant that he describes pharmaceuticals as ‘the poster child for the patent system’, arguing that 20 years for pharmaceuticals  is more than warranted given the  R&D that takes place.

The decision also puts the spotlight on generic drugs and the practice of evergreening.  The generics industry is huge - worth some R6 billion in South Africa alone - and major players in the local market include Aspen, Cipla Medpro and Adcock Ingram. What generics companies do essentially  is to replicate drugs that are no longer protected by patents -  in order to register a generic with the Medicines Control Council (MCC) you  simply need to show that you have mimicked the original in terms of dissolution and absorption, you don’t need to prove efficacy because that’s  already been established.  Because generics pose a threat to pharmaceutical companies, the issue of evergreening has become  very important. Indian patent law is known to be hostile to evergreening, but it’s been reported that there are patents for the new Glivec in a number of countries,  including the USA, China and Russia and South Africa.  So just what is the position in South Africa on this?

The South African Patents Act does not say anything about evergreening, and there have not been any decisions as far as I am aware. Generics companies do, however,  complain that the system works against them.  For starters, in  South Africa there is no examination of patent applications (expect for formalities), which means that  the only time that a patent is considered on its merits is if it’s challenged in court,  something that only really happens  as a response to a claim of  infringement. But, say the generics companies, even if they do want to contest the validity of a patent on the basis of evergreening/ lack of novelty – perhaps because the new patent comprises no more than a different manufacturing process or dissolution profile - the reality is that the pharmaceutical company will get an interim interdict because the ‘balance of convenience’ favours it, and the issue of the validity of the patent will be put off for another day (another year really!). Which means that, irrespective of the merits of the new patent, the pharmaceutical company can buy a few years extra protection.

It is for reasons like this that certain parties, including the Treatment Action Campaign (TAC), are calling for a reform of the patent System in South Africa. Such reform could mean amendment of the Patents Act to include clauses similar to those found in section 3 of the Indian Patents Act, which are perhaps a little more “politicised” and “generic friendly”, and the application of which made the Glivec decision in India less surprising. Intellectual property laws do, however, not receive a great deal of attention from government, and court cases are few and far between. Which means that it may be some time before we have clarity on the issue of evergreening!

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
Adams & Adams
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Adams & Adams
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions